Why is $NAMS moving today? · SEC 8-K archive

$NAMS SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $NAMS: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $NAMS filing catalyst

Why did $NAMS trigger an AI stock catalyst alert?

$NAMS triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: NewAmsterdam Pharma reports Q3 results, highlights first global EU approval for Ubeslo. Key points: - Received European Commission marketing approval for Ubeslo and Evlarco, marking obicetrapib's first global approval. - Q3 net loss per share narrowed to $(0.14) vs $(0.61) year-over-year; cash reserves stand at ~$643.1M. - Initiated Phase 2b SPINOZA Alzheimer's trial; PREVAIL interim analysis targeted for 4Q2026.

How did $NAMS stock react after the SEC filing?

After the SEC 8-K for $NAMS, observed market reaction: T0 price $19.90. Past moves do not guarantee future results.

Where can I get real-time $NAMS SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $NAMS via Telegram and the VIP Web Terminal from €10/month.

$NAMS

$NAMS – NewAmsterdam Pharma reports Q3 results, highlights first global EU approval for Ubeslo

NewAmsterdam Pharma Co N.V.

2026-11-04 00:00:00 UTC · SEC 8-K · All $NAMS

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

Received European Commission marketing approval for Ubeslo and Evlarco, marking obicetrapib's first global approval.
Q3 net loss per share narrowed to $(0.14) vs $(0.61) year-over-year; cash reserves stand at ~$643.1M.
Initiated Phase 2b SPINOZA Alzheimer's trial; PREVAIL interim analysis targeted for 4Q2026.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →